HCW Biologics wins USPTO patent allowance for HCW9302 use in alopecia areata treatment

PUBT · 2d ago
HCW Biologics wins USPTO patent allowance for HCW9302 use in alopecia areata treatment
  • HCW Biologics received a USPTO notice of allowance for patent claims covering use of HCW9302 to treat alopecia areata.
  • Move expands U.S. intellectual property protection for HCW9302, its lead IL-2-based immunotherapy program.
  • Phase 1 dose-escalation study in alopecia areata remains on track to complete in Q4 2026 with no dose-limiting toxicities reported.
  • Early data from the first two cohorts showed a positive response after a single 3 micrograms/kg monotherapy dose.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609020900PRIMZONEFULLFEED9819713) on September 02, 2026, and is solely responsible for the information contained therein.